(Reuters)- Mallinckrodt Plc (MNK.N) is exploring a sale of its generic drug unit, in a deal that could fetch as much as $ 2 billion and help pivot the specialty pharmaceutical maker toward higher -
margin branded drugs, according to people familiar with the matter.
The world's largest
drug manufacturer is facing steep competition from a slew of smaller generic players, and the recent loss of patent protection on its major
branded drug, Copaxone, is threatening Teva's profit
margins.
Tags for this Online Resume: Distribution, Entertainment, Forecasting, Pricing, Inventory, Retail, Advertising, e-Commerce,
Margin / P & L,
Brand Development, Customer Service, Strategy, Big Box, Mass, Club,
Drug, Supermarket, C - Stores, POS, Business Development